Resection of Recurrent Intracranial Tumors for Molecular Diagnostics in the Age of Precision Oncology: A Risk-Benefit Analysis

• Obada Alhalabi,
• Philip Dao Trong,
• Martin Jakobs,
• Antje Wick,
• Laila König,
• Felix Sahm,
• Andreas W. Unterberg,
• Christine Jungk

Affiliations

Obada Alhalabi

Department of Neurosurgery, Heidelberg University Hospital, Heidelberg, Germany

Philip Dao Trong

Department of Neurosurgery, Heidelberg University Hospital, Heidelberg, Germany

Martin Jakobs

Department of Neurosurgery, Heidelberg University Hospital, Heidelberg, Germany

Antje Wick

Clinical Cooperation Unit Neurooncology, German Cancer Research Center (DKFZ), Heidelberg, Germany; Department of Neurology and Neurooncology Program; National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany, Heidelberg, Germany

Laila König

4Department of Radiation Oncology, Heidelberg University Hospital; Heidelberg Ion Beam Therapy Centre (HIT); National Center for Radiation Oncology (NCRO), Heidelberg Institute for Radiation Oncology (HIRO), Heidelberg, Germany

Felix Sahm

Department of Neuropathology, Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany

Andreas W. Unterberg

Department of Neurosurgery, Heidelberg University Hospital, Heidelberg, Germany

Christine Jungk

Department of Neurosurgery, Heidelberg University Hospital, Heidelberg, Germany